

Sepsis Update Advisory Committee Interests Register

Register last updated: 21 October 2025

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Ann Hoskins	Chair	Direct non-financial professional and personal interests	Advocate / member of the British Association of Child and Adolescent PH.		Dec-2021	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Ann Hoskins	Chair	Direct non-financial professional and personal interests	Board Member, Plus Dane Housing Association	2016	May 2022	Ongoing	Declare and participate. Rationale: Not specific to the update of the guideline
Ann Hoskins	Chair	Direct financial	Independent Public Health Consultant			Ongoing	Declare and participate Rationale: Self-employed providing NHS services.
Samina Begum	Lay member	Nil	Nil	Nil	Nil	Nil	Nil
Louise Bradbury	Consultant Nurse for Outreach	Direct financial	Critical Care Outreach and Deteriorating Patient Lead, Watford General Teaching Hospital	Jan-21	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Tumena Corrah	Consultant in Acute Medicine	Non-financial professional and personal	Arberry J, Henry Z, Corrah T. A simple measure to improve sepsis documentation and coding. Clin Med (Lond) 2021; 21(3):222-225.	2021	May-22		Declare and participate Rationale: Not specific to the scope of the guideline

Tumena Corrah	Consultant in Acute Medicine	Non-financial professional and personal	Enoch DA, Cargill JS, Laing R, Herbert S, Corrah TW , Brown NM. Value of CT-guided biopsy in the diagnosis of septic discitis. J Clin Pathol 2008; 61(6):750-753.	Jun-08	May-22		Declare and participate Rationale: Not specific to the scope of the guideline No action needed other than process of open declaration.
Tumena Corrah	Consultant in Acute Medicine	Direct financial	Consultant in infectious Diseases and Acute Medicine and Honorary Senior Clinical Lecturer (Imperial College London)	Apr-15	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment at educational institution.
Peter Gosling	Lay Member	Nil	Nil	Nil	Nil	Nil	Nil
Alasdair Gray	Consultant in Emergency Medicine	Non-financial professional and personal	Co-Chief Investigator. Feasibility of 5% Albumin compared with Balanced crystalloid, intravenous fluid resuscitation in adult Sepsis patients presenting as an emergency to hospital: The ABC Sepsis Trial. Finished recruitment, in follow up. Feasibility trial	2020	May-22	Ongoing	Partial exclusion Rationale: Member was not allowed to participate in the drafting of recommendations on IV fluids.
Alasdair Gray	Consultant in Emergency Medicine	Non-financial professional and personal	Co-investigator. Vasopressors in Sepsis (EVIS). NIHR HTA programme (NIHR132594); (2021-2026). Pragmatic trial of low dose early vasopressor compared with current standard of care	2021	May-22	Ongoing	Partial exclusion Rationale: Member was not allowed to participate in the drafting of recommendations on vasopressors.

			in patients with sepsis presenting to UK EDs. Trial currently in set up.				
Alasdair Gray	Consultant in Emergency Medicine	Direct financial	Consultant in Emergency Medicine, NHS Lothian and Honorary Professor, University of Edinburgh	2021	May-22	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Alasdair Gray	Consultant in Emergency Medicine	Indirect financial	Co-applicant on an NIHR platform trial on biomarkers and prognosis for patients presenting to emergency care with presumed infection.		December-23		Declare and participate Rationale: The application was ultimately unsuccessful and was not funded.
Alasdair Gray	Consultant in Emergency Medicine	Direct financial	Consultancy work for MeMed for their infection biomarker. Fee for this work is to be paid to NHS Lothian.	January-24	Dec-23	Ongoing	Declare and participate Rationale: Not-specific. To be reviewed once searches are completed as this does connect to the scope. Updated with additional information from the member. The work conducted with MeMed was on a combination of three biomarkers. IP-10, CRP and TRAIL. These are connected to pneumonia not sepsis so not specific to the scope of this guideline.
Alasdair Gray	Consultant in Emergency Medicine	Direct non-financial professional and personal	Author on Albumin Versus Balanced Crystalloid for the Early Resuscitation of Sepsis: An Open Parallel-Group Randomized	Jun-24	Aug-24		Partial exclusion Rationale: Member was not allowed to participate in the drafting of recommendations on IV fluids.

			Feasibility Trial. The ABC-Sepsis Trial				
Jeremy Henning	Consultant in Critical Care Medicine	Direct financial	Consultant Intensive Care Medicine, South Tees NHS Foundation Trust	April-02	May-22	Ongoing	Declare and participate Rationale: salaried employment in the NHS.
Jeremy Henning	Consultant in Critical Care Medicine	Non-financial professional and personal	Local Principle Investigator for SEPTIC at James Cook University Hospital. Restricting early fluids in sepsis and PCR testing	February -24	February -24		Declare and Participate Rationale: Open declaration is sufficient mitigation. We are not including this study in our review and there is no personal financial benefit.
Tessa Lewis	General Practitioner	Non-financial professional and personal	Developed webinar & slide set on decision points for remote management of common infections. Topics included otitis media, sinusitis, cough and other common infections - Included within paid role as medical adviser to PHE primary care intervention unit/ TARGET toolkit	Dec-21	Oct-21	2022	Declare and participate Rationale: Not specific to the scope of the guideline
Tessa Lewis	General Practitioner	Non-financial professional and personal	Chair of the NICE Pneumonia update committee	Jul-22	Sep-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline
Tessa Lewis	General Practitioner	Direct financial	General practitioner (locum) with special interest in frailty including two days per week	Feb-25	Jul-25	Ongoing	Declare and participate

			at Powys Teaching Health Board				Updated July 2025 Rationale: Salaried employment in the NHS.
Tessa Lewis	General Practitioner	Non-financial professional and personal	Royal College of General Practitioners representative on UKHSA ESPAUR	Oct-22	Apr-23	Ongoing	Declare and participate. Rationale: A survey of anti-microbial resistance but not specific to sepsis.
Tessa Lewis	General Practitioner	Non-financial professional and personal	Royal College of General Practitioners representative on UK Standards for Microbiology Investigations steering committee.	Apr-23	Apr-23	Ongoing	Declare and participate. Rationale: Not specifically looking at Sepsis so not specific to the scope of the guideline.
Tessa Lewis	General Practitioner	Direct financial	Participated in a BMJ masterclass webinar: "Antimicrobial stewardship from the frontline – updates and opportunities". Honorarium paid via BMJ from <i>Fondazione Menarini</i> .	Nov-24	Dec-24	Nov-24	Declare and participate. Rationale: Anti-microbial stewardship is not a sepsis-specific topic and the talk whilst sponsored by the Menarini group was not about any specific pharmaceuticals.
Paddy McMaster	Co-Opted Paediatrician	Non-financial professional and personal	Member of the NICE Pneumonia Committee	Oct-23	May-24	Ongoing	Declare and participate Rationale: Membership on other NICE committees is not a conflict.
Paddy McMaster	Co-Opted Paediatrician	Non-financial professional and personal	On steering committee of UK Paediatric Antimicrobial Stewardship – lead for Antimicrobial Paediatric Guide	2019	May-24	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline

Paddy McMaster	Co-Opted Paediatrician	Direct Financial	Consultant in Paediatric Infectious Diseases at North Manchester General Hospital and Royal Manchester Children's Hospital	2011	May-24	Ongoing	Declare and participate Rationale: Salaried employment in the NHS
Paddy McMaster	Co-Opted Paediatrician	Non-financial professional and personal	BATCH study procalcitonin in suspected infection in children Biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: statistical analysis plan for the BATCH trial and PRECISE sub-study - PubMed (nih.gov)	2019	May-24	Ongoing	Declare and participate Rationale: Not in scope. The BATCH trial looked at procalcitonin in childhood sepsis.
Barry Murphy-Jones	Paramedic	Non-financial professional and personal	Murphy-Jones, B. & Shaw, J. (2016). Level of Sepsis Knowledge In UK Ambulance Services. <i>Emergency Medical Journal</i> , 33: e10-e11.	2016	May-22	Nil	Declare and participate Rationale: Not specific to the scope of the guideline
Barry Murphy-Jones	Paramedic	Direct financial	Senior Lecturer – Paramedic Science, University of Hertfordshire	Jan-22	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment in higher education.
Barry Murphy-Jones	Paramedic	Direct financial	Associate Lecturer, Angela Ruskin University	Nov-19	Oct-22	May-24	Declare and participate

							Rationale: Salaried employment in higher education.
Barry Murphy-Jones	Paramedic	Direct financial	Advanced Paramedic Practitioner – Critical Care, London Ambulance Service	Sep-17	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Barry Murphy-Jones	Paramedic	Non-financial professional and personal	ERC young Masterclass – potential peer reviewer for Resuscitation Plus	Sept-23	Sept-23	July-24	Declare and participate Not specific to the scope of the guideline
Barry Murphy-Jones	Paramedic	Non-financial professional and personal	Reviewer of the Association of Ambulance Chief Executives (AACE) Sepsis guidelines, incorporating NICE recommendations and other current evidence related to pre-hospital care. AACE produce the Ambulance JRCALC guidelines	Jun-24	Jun-24	Ongoing	Declare and participate Rationale: This is not in conflict with our recommendations and will not influence his role on the committee.
Marlies Ostermann	Consultant in Critical Care Medicine	Direct financial	Speaker honoraria from Fresenius Medical Care, Baxter and Biomerieux – “ <i>Acute kidney injury in critically ill patients</i> ”. (payment was used to support research studies)	Jan-20	May-22	Mar-22	Declare and participate Rationale: Not specific to the scope of the guideline
Marlies Ostermann	Consultant in Critical Care Medicine	Indirect financial	Research funding from Fresenius Medical Care, Baxter, Biomerieux and LaJolla Pharma (funding was paid to Guy’s & St Thomas)	Jan-19	May-22	Feb-22	Declare and participate Rationale: Not specific to the scope of the guideline

			Hospital London and was used for 2 research studies exploring the epidemiology of acute kidney injury in critically ill patients in the Intensive Care Unit)				
Marlies Ostermann	Consultant in Critical Care Medicine	Direct financial	Member of advisory committee for Mission Therapeutics and Pfizer for acute kidney injury pharmaceuticals	Jan-21	May-22	Feb-22	Declare and participate Rationale: Not specific to the scope of the guideline update
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Deputy Co-Chair of Surviving Sepsis Guidelines Committee	2019	May-22	2021	Declare and participate Rationale: Historic Chairing that concluded before Marlies Joined this committee.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Member of Surviving Sepsis Research Committee	July 2021	May-22	Ongoing	Declare and participate Rationale: Open declaration is sufficient mitigation.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Principal investigator of REVIVAL trial (RCT comparing the role of recombinant alkaline phosphatase in critically ill patients with sepsis and acute kidney injury)	2021	May-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Principal Investigator of CLASSIC trial (RCT comparing restrictive versus liberal fluid management in patients with septic shock) - Meyhoff TS, Hjortrup PB,	2020	May-22	June 2022	Declare and participate Rationale: Interest is in scope for the guideline update, and the study was identified during searches, it did not meet the

			Wetterslev J et al. Restriction of Intravenous Fluid in ICU Patients with Septic Shock.. N Engl J Med. 2022 Jun 30;386(26):2459-2470. doi: 10.1056/NEJMoA2202707				criteria for inclusion in the review.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Principal investigator of ATHOS III trial (RCT investigating the role of Angiotensin II in vasodilatory shock) - Khanna A, English SW, Wang XS et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoA1704154	2015	May-22	2017	Declare and participate Rationale: Interest is not specific to the scope of this update and open declaration is sufficient mitigation.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Director of Research, Chair of Standards Committee and Council member of Intensive Care Society UK	2020	May-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Chair of Research Committee of European Society of Intensive Care Medicine and Member of Executive Committee	2021	May-22	October 2023	Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Member of AKIN Committee of the American Society of Nephrology	2020	May-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline

Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Coordinator of European Sepsis Survey	2020	May-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Member of Royal Society of Medicine Critical Care Council	2020	May-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Spoden M, et al. Occurrence and Risk Factors for New Dependency on Chronic Care, Respiratory Support, Dialysis and Mortality in the First Year After Sepsis. Front Med (Lausanne). 2022 May 19;9:878337. doi: 10.3389/fmed.2022.878337. PMID: 35665356; PMCID: PMC9162443..	2022	May-22	May-22	Declare and participate Rationale: Not specific to the scope of the guideline
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Bakker J et al. Current practice and evolving concepts in septic shock resuscitation. Intensive Care Med 2021;48:148-163	2021	May-22	2021	Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Evans L et al. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. Crit Care Med 2021;49(11):1971-1982	2021	May-22	2021	Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation.

Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Evans L et al. Surviving sepsis campaign: international guidelines for the management of sepsis and septic shock. Intensive Care Med 2021;47(11):1181-1247	2021	May-22	2021	Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	De Backer D et al. Challenges in the management of septic shock: a narrative review. Intensive Care Med 2019;Feb 11	2019	May-22	Feb-19	Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation.
Marlies Ostermann	Consultant in Critical Care Medicine	Direct financial	Consultant in Critical Care & Nephrology, Guy's and St. Thomas Hospital	Nov-05	May-22	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Marlies Ostermann	Consultant in Critical Care Medicine	Non-financial professional and personal	Honorary Senior Lecturer, King's College London	Dec-09	May-22	Sept 21	Declare and participate Rationale: Non-salaried employment in educational services.
Marlies Ostermann	Consultant in Critical Care Medicine	Direct financial	Professor in Intensive Care Medicine, King's College London	Sep-21	May-22	Ongoing	Declare and participate Rationale: Salaried employment in educational services.
Marlies Ostermann	Consultant in Critical Care Medicine	Direct financial	Member of advisory board meeting for Alexion on acute kidney injury	Apr-22	May-22	Apr-22	Declare and participate Rationale: Interest is not specific and open declaration is sufficient mitigation.

Ashley Reed	Emergency Consultant	Direct financial	Consultant Practitioner (Paramedic), Southend University Hospital NHS Foundation Trust	Feb-23	Apr-24	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Ashley Reed	Emergency Consultant	Direct financial	Visiting lecturer at the University of Hertfordshire – teaching on paramedic science BSc and MSc modules	Sep-21	May-24	Ongoing	Declare and participate Rationale: Salaried employment in higher education
Ashley Reed	Emergency Consultant	Non-financial professional and personal	Principal Investigator in an NIHR Study – Opt-out testing for HIV, Hep B and Hep C in the Emergency Department for Southend ED site.	Apr-24	Apr-24	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Ashley Reed	Emergency Consultant	Non-financial professional and personal	Prepared case report for publication of: “Recurrent skin and soft tissue infections (SSTIs) in three family members caused by meticillin resistant staphylococcus aureus (MRSA) with panton-valentine leukocidin (PVL) endotoxin.”	Apr-24	Apr-24	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Ashley Reed	Emergency Consultant	Non-financial professional and personal	Principal Investigator on research study – DrUBER: Drone Network for Medical Emergency Delivery.	Sep-24	Sep-24		Declare and participate Rationale: Not specific to the scope of the guideline update
Ashley Reed	Emergency Consultant	Non-financial professional and personal	Professional Doctorate student with Salford University	Sep-24	Sep-24		Declare and participate

							Rationale: Not specific to the scope of the guideline update
Giovanni Satta	Consultant Microbiologist/Infectious Disease Specialist	Direct financial	Consultant in Infection (Microbiology and Infectious Diseases) and Infection Control Doctor, University College London Hospitals	Feb-21	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment at educational institution.
Giovanni Satta	Consultant Microbiologist/Infectious Disease Specialist	Direct financial	Associate Professor, University College London Hospitals	Feb-21	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment in educational services.
Mervyn Singer	Topic Adviser	Direct financial	Professor of Intensive Care Medicine and Director, Centre for Intensive Care Medicine, Division of Medicine, University College London	Oct-2001	June-23	Ongoing	Declare and participate Rationale: Salaried employment at educational institution.
Mervyn Singer	Topic Adviser	Direct financial	Advisory board member, Enlivex - Israeli company developing a novel cell-based therapy for sepsis	Dec-19	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Direct financial	Advisory board member, deepUII – Spanish company developing a molecular diagnostic for pathogens (transcriptomic technology) which they are planning to combine with a Raman spectroscopic approach for	Apr-21	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update.

			rapid assessment of antibiotic susceptibility.				
Mervyn Singer	Topic Adviser	Direct financial	Advisory board member, Safeguard Biosystems – US company developing a molecular diagnostic for pathogens (transcriptomic technology)	Dec-21	June-23	Ongoing	Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the member agreed to withdraw from this sat out of discussion the drafting of recommendations for these reviews.
Mervyn Singer	Topic Adviser	Direct financial	Advisory board member, Aptarion - Swiss company developing a novel drug for sepsis	May-22	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Direct financial	Advisory board member, Roche Diagnostics – multinational company developing novel pathogen diagnostics	Nov-22	June-23	Feb-23	Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews
Mervyn Singer	Topic Adviser	Direct financial	Advisory board member, Matisse Pharmaceuticals – Dutch company developing a novel drug for sepsis - A modified heparin that binds	Sept-23	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update

			histones released from neutrophils in sepsis.				
Mervyn Singer	Topic Adviser	Non-financial professional and personal	Council member (and past-Chair) International Sepsis Forum – group of sepsis experts who organise a yearly international sepsis meeting, colloquia, and provide advice to Industry	2009	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Non-financial professional and personal	Member, Acute Deterioration Board, NHS England	2021	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline
Mervyn Singer	Topic Adviser	Non-financial professional and personal	Vice-Chair, Academy of Medical Royal Colleges Working Group on initial antibiotic treatment for sepsis	2019	June-23	2023	Declare and participate Rationale: Historic chairing that ended as the individual joined this committee in June 2023
Mervyn Singer	Topic Adviser	Non-financial professional and personal	Trustee for the University College London Hospitals NHS Foundation Trust (UCLH) Charity. The role involved giving input into how money was invested and spent (applications for internal hospital grants, quality improvement projects, patient experience enhancements etc.)	2017	June-23	March-23	Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation.
Mervyn Singer	Topic Adviser	Non-financial professional and personal	UCL Technology Fund Award to develop novel in-house therapy for sepsis	2021	June-23	2023	Declare and participate

							Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Non-financial professional and personal	Principal clinical investigator (in conjunction with Oxford Optronix) - Wellcome Trust/Dept Health Award to develop novel monitor for monitoring organ perfusion adequacy	2016	June-23	2023	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Non-financial professional and personal	Pre-symptom Health – unpaid advisor to Ministry of Defence (DSTL) spin-off company developing novel sepsis diagnostic test	2019	June-23	Ongoing	Complete exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews
Mervyn Singer	Topic Adviser	Non-financial professional and personal	Clinical studies performed on the UCLH intensive care unit on novel sepsis and pathogen diagnostics - Gentian, Biomerieux	2019	June-23	Ongoing	Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the member agreed to withdraw from this discussion and the drafting of recommendations for these reviews.
Mervyn Singer	Topic Adviser	Direct financial	Rosetrees Trust Award – preclinical studies to enhance activity of existing antibiotics	2021	June-23	2023	Declare and participate

			by incorporation into cationic liposomes and addition of DNA nanotubes				Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Indirect financial	Deltex Medical – UK company making haemodynamic monitoring device- royalties and advisory board honorarium paid into my Research Fund held by UCLH Charity. The member has dual control over these funds along with an intensive care colleague.	2000	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Indirect financial	Biotech – German company producing immunoglobulin therapy for sepsis - advisory board - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague.	2016	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Indirect financial	Biomerieux – French company developing novel pathogen diagnostics - advisory board and educational videos - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague.	2019	June-23	Ongoing	Complete Exclusion Rationale: This is specific to the recommendations being updated in review questions 1 and 2, so the individual sat out of the discussion and recommendation making for these reviews
Mervyn Singer	Topic Adviser	Indirect financial	Fresenius - German company producing	June-23	June-23	Oct-23	Declare and participate

			intravenous fluids – chair of satellite meeting, speaker at educational meeting - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague.				Rationale: Not specific to the scope of the guideline update as it was about fluids relating to renal replacement as opposed to IV.
Mervyn Singer	Topic Adviser	Indirect financial	Hemotune – Swiss company developing extracorporeal therapy for sepsis - advisory board - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague.	Sept-21	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Indirect financial	NewB - Hong Kong-based company developing new therapy for ischaemia-reperfusion injury - chair of DSMC honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague.	Oct-18	June-23	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Indirect financial	Pfizer – multinational company and manufacturer of novel antibiotic - speaking at satellite meeting - honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds	Mar-23	June-23	Mar-23	Declare and participate Rationale: Not specific to the scope of the guideline update

			along with an intensive care colleague.				
Mervyn Singer	Topic Adviser	Indirect financial	Pfizer - multinational company and manufacturer of novel antibiotic - advisory Board - honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds along with an intensive care colleague.	Nov-22	June-23	Nov-22	Declare and participate Rationale: Not specific to the scope of the guideline update
Mervyn Singer	Topic Adviser	Indirect financial	ProMISe (funded by NIHR HTA Programme) Co-funding applicant and contributor - Protocolized Management in Sepsis (ProMISe): A multi-centre, randomized controlled trial of the clinical and cost-effectiveness of early goal-directed protocolized resuscitation for emerging septic shock. https://pubmed.ncbi.nlm.nih.gov/26597979/	Nov-19	Dec-23		Declare and participate Rationale: This review was not included in our evidence reports.
Mervyn Singer	Topic Adviser	Indirect financial	NIHR Efficacy and Mechanism Evaluation Programme Award 15/99/02 Co-funding applicant and contributor - Biomarker-guided Duration of Antibiotic treatment in hospitalised Patients with moderate to	Apr-23	Dec-23		Declare and participate Rationale: This review was not included in our evidence reports.

			severe Sepsis. The ADAPT-Sepsis Trial. https://journals.sagepub.com/doi/full/10.1177/17511437231169193				
Mervyn Singer	Topic Adviser	Indirect financial	NIHR Efficacy and Mechanism Evaluation Programme Award Co-funding applicant and contributor - Study into the Reversal of Septic Shock with Landiolol (STRESS-L) https://pubmed.ncbi.nlm.nih.gov/33593781/	Feb-21	Dec-23		Declare and participate Rationale: This review was not included in our evidence reports.
Mervyn Singer	Topic Adviser	Indirect financial	NIHR Research Award 17/136/02 Co-funding applicant and contributor - Sepsis Trials in Critical Care (SepTIC) https://fundingawards.nihr.ac.uk/award/17/136/02	May-22	Dec-23	Ongoing	Declare and participate Rationale: This review was not included in our evidence reports.
Mervyn Singer	Topic Adviser	Indirect financial	EU DLV-676129 Marie Curie Innovative Training Network Award [€546,576] European Sepsis Academy: towards new biomarkers to improve sepsis management (Principal Investigator at UCL)	Mar-16	Dec-23	Feb-20	Declare and participate Rationale: This review was not included in our evidence reports.

Mervyn Singer	Topic Adviser	Indirect financial	Innovate UK Biomedical Catalyst Early Stage Award to Mologic Ltd 82371-510474 [£1,255,191] Principal Clinical Investigator Sepsis Alert Test	2017	Dec-23	2019	Declare and participate Rationale: This review was not included in our evidence reports.
Mervyn Singer	Topic Adviser	Indirect financial	MRC Research Award (MR/T025441/1) [£841,264] Reeder JB, Singer M. Co-funding applicant and contributor - Optimisation of the manufacture of a homogeneous synthetic hemoglobin as a novel Oxygen Therapeutic / Blood Substitute	Nov-20	Dec-23	Jul-23	Declare and participate Rationale: This review was not included in our evidence reports.
Mervyn Singer	Topic Adviser	Indirect financial	UCL Technology Fund Award (UTF-21-006) [£150,000] Singer M, Kleyman A, Press A, Bauer M. Principal funding applicant - Development of a phytosterol therapy for sepsis-induced myocardial depression	2022	Dec-23	2023	Declare and participate Rationale: This review was not included in our evidence reports.
Mervyn Singer	Topic Adviser	Direct financial	Will sit on an advisory board for Sanofi as they develop a new vaccine to prevent urosepsis. Honorarium to be paid.	Oct-24	Nov-24	Ongoing	Declare and participate Rationale: Sanofi are not currently manufacturing any pharmaceuticals in scope.
Mervyn Singer	Topic Adviser	Direct financial	Will sit on an advisory board for Bayer as they develop a new sepsis drug. Information	Jan-25	Nov-24	Ongoing	Declare and participate

			to follow after contract arrangements. Honorarium will be paid to his into his research fund.				Rationale: Bayer are not currently manufacturing any pharmaceuticals in scope, as of September 2025, Bayer are still deliberating on taking this forward to clinical trials so there have been no developments
Kirstie Tomlinson	Mental Health Professional (co-opted)	Non-financial professional and personal	Advanced Clinical Practitioner Mental Health Services for Older People, Nottinghamshire Healthcare NHS Foundation Trust.	2022	Apr-24	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Savio Fernandes (resigned from the committee January 2024)	Consultant Haemoncologist	Direct financial	Consultant in Haematology, Didley Group NHS Foundation Trust		Oct-22	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Erum Khan (resigned from the committee September 2024)	Consultant Obstetrician	Non-financial professional and personal	RCOG Patient Safety Committee member	May-22	May-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline
Erum Khan (resigned from the committee September 2024)	Consultant Obstetrician	Direct financial	Consultant Obstetrician and Gynaecologist, Milton Keynes University Hospital	Apr-15	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Sally Wood (resigned from the committee June 2024)	Consultant Nurse in Emergency Medicine	Indirect financial	Successful grant from Pfizer to appoint a colleague in a secondment role at NUH for 12months leading on blood culture improvement project.	Oct-21	May-22	Apr-23	Declare and participate Rationale: Not specific to the scope of the guideline

Sally Wood (resigned from the committee June 2024)	Consultant Nurse in Emergency Medicine	Non-financial professional and personal	"Predicting 30-day mortality in patients with sepsis; an exploratory analysis of process or care and patient characteristics" (2018) <i>The journal of Intensive Care Society</i> . Sanderson, M., Moppett, I., Chikhani, M., Simmonds, M., Wood, S., McKeever, T.	2018	May-22		Declare and participate Rationale: Not specific to the scope of the guideline
Sally Wood (resigned from the committee June 2024)	Consultant Nurse in Emergency Medicine	Non-financial professional and personal	"Improving outcome of sepsis on the ward: introducing the sepsis six bundle" Burke, J., Wood, S., Hermon, A., Szakmany, T., Jan 2019 <i>Nursing in Critical Care BACCN</i> . 24 (1)	Jan-19	May-22		Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration.
Sally Wood (resigned from the committee June 2024)	Consultant Nurse in Emergency Medicine	Non-financial professional and personal	"Surviving sepsis beyond intensive care: survival rates at one decade." Dec 2018. Patel, R., Wood, S.D., Ford, A., Hutchinson, A., Weston, V., Simmonds, M., Chikhani, M. <i>Intensive care State of the art 2018 Conference</i>	Dec-18	May-22		Declare and participate Rationale: Not specific to the scope of the guideline
Sally Wood (resigned from the committee June 2024)	Consultant Nurse in Emergency Medicine	Non-financial professional and personal	"Sepsis Bags: Simple method to increase procedure compliance with sepsis six on the ward" (2013) Burke, J., Smith, L., <u>Wood, S.</u> , Hermon, A., Szakmany, T. <i>Poster presentation at ESICM Annual Congress, Paris: LIVES 2013.</i>	2013	May-22		Declare and participate Rationale: Not specific to the scope of the guideline

Sally Wood (resigned from the committee June 2024)	Consultant Nurse in Emergency Medicine	Direct financial	Recognise and Rescue and Sepsis Matron, Nottingham University Hospitals NHS Trust	2019	Oct-22	Ongoing	Declare and participate Rationale: Salaried employment in the NHS.
Sally Wood (resigned from the committee June 2024)	Consultant Nurse in Emergency Medicine	Non-financial professional and personal	Member of the UK Sepsis Practitioner Forum	Oct-22	Oct-22	Ongoing	Declare and participate Rationale: Not specific to the scope of the guideline.

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.